Science and Medicine
Technology Platforms Products Center
About Us
Full Value Chain
News
Investor Relations
Announcements and Circulars Corporate Governance Investor Inquiry
Contact Us
SC TC EN
SC TC EN
Science and Medicine
Technology Platforms Products Center
About Us
Full Value Chain
News
Investor Relations
Announcements and Circulars Corporate Governance Investor Inquiry
Contact Us
景助达®

Product List
Product Overview
Guideline Recommendations
Academic Publications
景助达®

Entinostat Tablets

Triple mechanisms
Reverse drug resistance, Multiple Antitumor Effects, Immunomodulation
Triple mechanisms
Proven Efficacy
Dual Benefits in PFS & OS
Proven Efficacy
Safe & Convenient
Oral Once-Weekly, minor Adverse Events
Safe & Convenient
The following product information is intended for use by healthcare professionals only.
The following product may not have been approved and/or licensed for marketing in all countries where this website is accessible.
景助达®
Directions for Use Download
(for medical professionals only)
Adverse Event Reporting

Email: pv@eddingpharm.com

Hotline: 0512-67611023

Product information stated by NMPA in Approved Drug Catalog of China.

【Name】

Generic Name：Entinostat Tablets

Brand Name：景助达® 

Chinese Pinyin：Entisita Pian
【Ingredients】

Active Ingredient:  Entinostat

Excipients：Mannitol, Sodium Carboxymethyl Starch (CMS-Na), Hydroxypropyl Cellulose (HPC), Potassium Bicarbonate, Magnesium Stearate, Film-Coating Premix (Enteric-Soluble Type) [containing Hydroxypropyl Methylcellulose (HPMC), Talc, Titanium Dioxide, Red Iron Oxide/Yellow Iron Oxide, Polyethylene Glycol (PEG)].

【Appearance】

Pink to light red (1mg) or yellow (5mg) film-coated tablet, which almost white after removing the coating.

【Indications】

in combination with an aromatase inhibitor for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.

【Specification】
（1）1mg；（2）5mg
For detailed product information, please download the full package insert (PDF).

Directions for Use Download
(for medical professionals only)
Adverse Event Reporting

Email: pv@eddingpharm.com

Hotline: 0512-67611023

Guideline Recommendations
CHINA ANTI CANCER ASSOCIATION & Oncology Society of Chinese Medical Association:Guidelines and norms for the diagnosis and treatment of breast cancer（2025）

Second-line and later-line treatment for patients with HR+/HER2- advanced breast cancer: for patients who have previously used cdk4/6 inhibitors, entinostat combined with a switched aromatase inhibitor (AI) is recommended.

Guidelines for diagnosis and treatment of breast cancer（2022）

Both premenopausal and postmenopausal patients can consider combined targeted therapy (HDAC inhibitors, etc.) on the basis of endocrine therapy.

Academic Publications
Abstract GS1-06: A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer
Journal Name: 2021 SABCS
Year: 2021
Read More

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.

Journal Name: 2024 ASCO
Year: 2024
Read More

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

Journal Name: 2023 Acta Pharmaceutica Sinica B
Year: 2023
Read More
Technology Platforms
Product Center
About Us
Full Value Chain
News
Investor Relations
Contact Us

沪ICP备2021007464号

Copyright © 2025 design by EDDING

药监局备案号: (沪) -非经营性-2021-0038